Unrecognized mutations in DPYD* 2 A wild-type rectal cancer patients receiving postoperative 5-FU-based chemotherapy - do they have a clinical impact?

Cancer Chemother Pharmacol · 2025 · PMC12259744 · PMID 40659880

Europe PMC DOI

hedged sentences

0.0530

closest p · 1.1× alpha

0.0600

boldest claim

The sentences

failed to reach statistical significancep = 0.053so close (0.05 < p ≤ 0.1)

At the CTx cycle level, the prediction of dose reduction narrowly failed to reach statistical significance for the mutation cohort ( p = 0.053 Table A.15).

also in 1,359 other papers

near-significantp = 0.057so close (0.05 < p ≤ 0.1)

Multivariable Cox regression analysis identified HapB3 status as a near-significant predictor of reduced DFS (HR 3.77; p = 0.057), suggesting a potential prognostic role independent of overt toxicity or dose adjustments.

also in 699 other papers

narrowly non-significantp = 0.06so close (0.05 < p ≤ 0.1)

In addition, when looking at the number of 5-FU dose reductions at the patient level, study participants with newly diagnosed het_HapB3 status had a higher, but narrowly non-significant risk of 5-FU dose reductions ( p = 0.06, Table A.16) below the cut-off of 75% of the planned 5-FU dose compared to DPYD -WT carriers.

also in 3 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.